Charles Buess, MD
Hematology & Oncology · Anchorage, AKNPI 1124548284
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,750 of the $4,514 with a category attached, or 60.9%. Beigene USA, Inc. accounts for 60.9% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2024 at $2,950 and has fallen 86.1% since, to $411 in 2025.
Across 62 payments — averaging $72.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Beigene USA, Inc.$3K
- Johnson & Johnson$198
- Novartis$165
- Regeneron Healthcare Solutions, Inc.$126
- Incyte Corporation$111
- Genentech USA, Inc.$108
- plus $1K from 23 others
What the payments were for
- Speaking & faculty fees$2,75061%
- Food & beverage$1,38031%
- Education$3859%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Beigene USA, Inc. | 1 | $2,750 |
| Johnson & Johnson | 2 | $198 |
| Novartis | 7 | $165 |
| Regeneron Healthcare Solutions, Inc. | 4 | $126 |
| Incyte Corporation | 5 | $111 |
| Genentech USA, Inc. | 5 | $108 |
| Seagen Inc. | 1 | $100 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $99 |
| Sanofi-aventis U.S. LLC | 1 | $86 |
| AbbVie | 3 | $85 |
| Pfizer | 4 | $83 |
| E.r. Squibb & Sons, L.L.C. | 3 | $77 |
| Merck | 3 | $65 |
| Rigel Pharmaceuticals, Inc. | 3 | $50 |
| Gilead | 2 | $47 |
| Karyopharm Therapeutics Inc. | 2 | $45 |
| Sobi, Inc | 2 | $44 |
| Morphosys, US Inc. | 2 | $40 |
| Jazz Pharmaceuticals Inc. | 1 | $31 |
| Astellas Pharma US Inc | 1 | $30 |
| Sanofi | 1 | $27 |
| Blueprint Medicines Corporation | 1 | $25 |
| Beone Medicines USA, Inc. | 1 | $24 |
| Amgen | 1 | $23 |
| ADC Therapeutics America, Inc. | 1 | $17 |
| Epizyme, Inc. | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Genmab U.S., Inc. | 1 | $15 |
| Taiho Oncology, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRUKINSA$2,750
How this compares
Too few hematology & oncology providers in Alaskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 26 | $298 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Anchorage
- Steven LiuAnchorage$35K
- Max RabinowitzAnchorage$14K
- Mary KlixAnchorage$13K
- Mary StewartAnchorage$9K
- Kendal WebbAnchorage$8K
- Natalie WallaceAnchorage$8K
- Shannon SmileyAnchorage$6K
- Anusiyanthan MariampillaiAnchorage$4K
- Theodore KimAnchorage$2K
- Ellen ChirichellaAnchorage$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.